Institute Group Leaders awarded promotions by the University
We are delighted to announce that several of our Group Leaders have been promoted in the University of Cambridge Senior Academic Promotions.
James Brenton, Sarah Bohndiek and Doug Winton have been promoted to Professors, while Florian Markowetz and Nitzan Rosenfeld have been promoted to Directors of Research. All promotions will take effect from 1 October 2020.
James Brenton
Dr James Brenton has been promoted to Professor of Ovarian Cancer Medicine in the Department of Oncology. Brenton’s research focuses on understanding the molecular complexity of ovarian cancer to improve treatment and patient outcome.
Sarah Bohndiek
Dr Sarah Bohndiek has been promoted to Professor of Biomedical Physics in the Department of Physics. Her group focuses on developing novel imaging approaches that can be applied to understand the role of the tumour microenvironment in cancer progression.
Doug Winton
Dr Doug Winton has been promoted to Professor of Epithelial Biology in the Department of Oncology. His team investigates the cancer cells in the intestinal epithelium to understand the probability of their survival and expansion at each stage and how this varies with different mutations.
Florian Markowetz
Dr Florian Markowetz has been promoted to Director of Research. His team develops computational methods to link genomic profiles with quantitative measures of phenotypes, leading towards a comprehensive systems genetics understanding of cancer.
Nitzan Rosenfeld
Dr Nitzan Rosenfeld has been promoted to Director of Research. Nitzan’s expertise is in liquid biopsy and translational cancer research. His research group has established applications of circulating tumour DNA (ctDNA) sequencing to analyze ctDNA from blood samples of cancer patients.
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more